GMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Globus Medical Inc (GMED) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial performance, positive analyst sentiment, and a credible growth trajectory. Despite short-term price weakness and insider selling, the long-term fundamentals and growth prospects outweigh the negatives.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 32.608, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its support level of 89.056, with resistance at 96.718. Overall, the technical indicators suggest a mixed short-term outlook but a stable long-term trend.
Strong Q4 financial performance with 25.73% YoY revenue growth, 430.44% YoY net income growth, and 442.11% YoY EPS growth.
Positive analyst sentiment with multiple price target upgrades and buy ratings, citing impressive earnings and growth potential in the US Core Spine market.
Bullish moving averages indicating long-term upward momentum.
Insider selling has increased by 389.20% over the last month, which could indicate a lack of confidence from insiders.
Short-term price weakness with a -1.29% regular market change and -0.32% post-market change.
Neutral hedge fund activity and no significant trading trends.
In Q4 2025, Globus Medical reported revenue of $826.42M (+25.73% YoY), net income of $140.59M (+430.44% YoY), EPS of $1.03 (+442.11% YoY), and a gross margin of 64.85% (+17.12% YoY). These results highlight strong growth and profitability improvements.
Analysts are highly positive on GMED, with multiple price target upgrades in the range of $104-$123 and consistent buy/overweight ratings. Analysts highlight impressive Q4 earnings, credible EBITDA margin expansion, and growth potential in the US Core Spine market.
